Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2006

View Archived Issues

Novel treatment strategies for cancer covered in recent patent literature

Recent patents describe new analgesic agents

Recent patents describe novel agents for anxiety, depression, psychosis etc.

Recent Universitaetsklinikum Muenster patent discloses novel diagnostic agents

Amoxicillin PULSYS demonstrates bacterial eradication in adults and adolescents

Visual acuity stabilization eight weeks after a single dose of Sirna-027

RabiCide to enter preclinical testing for rabies by 2007

Acrux and Population Council amend transdermal contraceptive agreement

Novartis, Schering-Plough to develop once-daily therapy for asthma and COPD

Additional information for Herceptin sBLA deemed major amendment

Gilead completes acquisition of Corus Pharma

Genzyme seeks to expand European label of Synvisc

Pharmexa discontinues phase II study of HER-2 Protein AutoVac

Approvable letter for eprodisate for AA amyloidosis

Delta opioid agonist provides effective analgesia in preclinical bone cancer pain

Jak2 validated as a therapeutic target for CML

Phase IIa asthma study of LAB CGRP completes enrollment

Nastech studies PYY3-36 nasal spray in dose-ranging obesity study

Depomed completes phase I study with GERD compound

DG-051 enters phase I for prevention of heart attack

Phase II trial studies Iomai's vaccine patch for travelers' diarrhea

Targeting 5-HT2A receptor-mediated nociception relieves painful symptoms following tissue injury

PI3Kdelta inhibition with IC-87114 has shown benefit in a murine model of allergic asthma

Galvus filed for European approval in type 2 diabetes

Soltamox launched in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.